SUPERNUS PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M |
| Cost of revenue | $74.6M | $77.9M | $83.8M | $87.2M | — |
| Selling, general & administrative | $485.6M | $321.6M | $336.4M | $377.2M | $304.8M |
| Research and development | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M |
| Operating income | -$62.3M | $81.7M | -$5.3M | $46.1M | $86.0M |
| Interest expense | $0 | $0 | $2.4M | $7.1M | $19.7M |
| Pretax income | -$49.0M | $97.9M | $2.8M | $60.7M | $73.2M |
| Income tax expense | -$10.5M | $24.0M | $1.5M | $32,000 | $19.8M |
| Net income | -$38.5M | $73.9M | $1.3M | $60.7M | $53.4M |
| Balance Sheet | |||||
| Cash and equivalents | $128.4M | $69.3M | $75.1M | $93.1M | $203.4M |
| Current assets | $644.2M | $686.1M | $493.1M | $734.2M | $601.6M |
| Total assets | $1.5B | $1.4B | $1.3B | $1.7B | $1.7B |
| Current liabilities | $338.2M | $292.4M | $290.2M | $688.0M | $315.4M |
| Total liabilities | $390.9M | $332.3M | $356.2M | $816.3M | $873.3M |
| Stockholders' equity | $1.1B | $1.0B | $921.5M | $886.2M | $815.9M |
| Cash Flow Statement | |||||
| Cash from operations | $47.3M | $172.0M | $111.1M | $116.8M | $127.1M |
| Depreciation and amortization | $91.6M | $80.4M | $84.9M | $85.5M | $32.6M |
| Stock-based compensation | $33.1M | $27.8M | $26.8M | $17.6M | $17.9M |
| Capital expenditure | $1.3M | $725,000 | $551,000 | $412,000 | — |
| Free cash flow | $46.0M | $171.2M | $110.5M | $116.4M | — |
| Impairments | $0 | $0 | $0 | — | — |
Shares outstanding 58.0M · Free float 80.7%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.